AstraZeneca Pharmaceuticals LP
2501 articles with AstraZeneca Pharmaceuticals LP
-
LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.
-
Ionis and AstraZeneca to develop and commercialize eplontersen
12/7/2021
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced it has entered into a strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis.
-
Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.
-
Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.
-
Scientists from Cardiff University and the Arizona State University believe they have found the likely cause of blood clotting in some recipients of the Oxford-AstraZeneca COVID-19 vaccine.
-
After Sobi agreed to be acquired by Advent International and GIC Special Investments, the deal has fallen through after AstraZeneca withheld its 8% stake from the buyout offer.
-
Two years into the COVID-19 pandemic, countries are reporting the fourth wave of rising cases, driven mainly by the Delta variant, although Omicron has everybody concerned. Here’s a look.
-
The U.S. Centers for Disease Control and Prevention (CDC) reported that the Omicron variant of COVID-19 had been identified in California.
-
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
11/24/2021
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:AZN) have initiated SACHI, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”), in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (“EGFR”) TKI, TAGRISSO® (osimertinib).
-
It's been a busy week so far, with new discovery facilities launched in the biotech space.
-
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
While COVID-19 appears to be battling back in cold-weather states in the U.S. and parts of Europe, researchers continue to study vaccine efficacy and new approaches to dosing. Here's a look.
-
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
11/18/2021
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global TROPION-Breast01 phase 3 trial evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).
-
Lung Cancer Research Foundation and AstraZeneca Announce Research Grant Awards
11/18/2021
The Lung Cancer Research Foundation and AstraZeneca have announced five research grant awards focused on understanding epidermal growth factor receptor inhibitor and immunotherapy resistance, totaling $900,000; giving each project $180,000 over a two-year period.
-
Monoclonal antibodies have proven to be an important therapeutic option in the ongoing battle against COVID-19.
-
The FDA and CDC will soon decide on Pfizer-BioNTech’s request for an Emergency Use Authorization for the booster shot for their COVID-19 vaccine.
-
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
11/17/2021
AstraZeneca has been granted Fast Track Designation in the United States (US) for the development of LOKELMA® (sodium zirconium cyclosilicate) to reduce arrhythmia-related cardiovascular outcomes in patients on chronic hemodialysis with recurrent hyperkalemia (HK).
-
Race is Heating Up for the First RSV Vaccine
11/17/2021
The market is expected to be worth $4.2 billion by 2027, with a CAGR of 14.9% between 2021 and 2027. -
Three companies have posted major developments in the field of heart disease therapy.
-
If bentracimab continues to yield the desired results through the rest of the Phase III study, PhaseBio will be on track to file a Biologics License Application in mid-2022.